CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC

被引：4
|
作者：
Pacheco, Jose M. [1 ]
Schenk, Erin L. [1 ]
机构：
[1] Univ Colorado, Dept Internal Med, Div Med Oncol, Ctr Canc, Anschutz Med Campus,1665 Aurora Court, Aurora, CO 80045 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
基金：
美国国家卫生研究院;
关键词：
CELL LUNG-CANCER; PATHWAY;
D O I：
10.1016/j.jtho.2021.01.1623
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：509 / 511
页数：3
相关论文
共 50 条
  • [1] Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target
    Le, Xiuning
    Negrao, Marcelo, V
    Reuben, Alexandre
    Federico, Lorenzo
    Diao, Lixia
    McGrail, Daniel
    Nilsson, Monique
    Robichaux, Jacqulyne
    Munoz, Irene Guijarro
    Patel, Sonia
    Elamin, Yasir
    Fan, You-Hong
    Lee, Won-Chul
    Parra, Edwin
    Soto, Luisa Maren Solis
    Chen, Runzhe
    Li, Jun
    Karpinets, Tatiana
    Khairullah, Roohussaba
    Kadara, Humam
    Behrens, Carmen
    Sepesi, Boris
    Wang, Ruiping
    Zhu, Mingrui
    Wang, Linghua
    Vaporciyan, Ara
    Roth, Jack
    Swisher, Stephen
    Haymaker, Cara
    Zhang, Jianhua
    Wang, Jing
    Wong, Kwok-Kin
    Byers, Lauren A.
    Bernatchez, Chantale
    Zhang, Jianjun
    Wistuba, Ignacio I.
    Gibbons, Don L.
    Akbay, Esra A.
    Heymach, John, V
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 583 - 600
  • [2] The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma
    Soleimani, Anvar
    Farshchi, Helale Kaboli
    Mirzavi, Farshad
    Zamani, Parvin
    Ghaderi, Amir
    Amini, Yousef
    Khorrami, Shadi
    Mashayekhi, Kazem
    Jaafari, Mahmoud Reza
    BIOCHIMIE, 2020, 176 : 21 - 30
  • [3] Another Pirate in the Red Ocean? CD73-Targeted Therapy in EGFR-Mutated NSCLC
    Horinouchi, Hidehito
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 552 - 555
  • [4] Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer
    Theard, Patricia L.
    Sheffels, Erin
    Sealover, Nancy E.
    Linke, Amanda J.
    Pratico, David J.
    Kortum, Robert L.
    ELIFE, 2020, 9
  • [5] Identification of protein X as a potential therapeutic target against EGFR-mutated cancers
    Tsukumo, Yoshinori
    Ohoka, Nobumichi
    Naito, Mikihiko
    Suzuki, Takayoshi
    CANCER SCIENCE, 2023, 114 : 425 - 425
  • [6] Potential of CD73 as a target for cancer immunotherapy
    Jadidi-Niaragh, Farhad
    IMMUNOTHERAPY, 2019, 11 (16) : 1353 - 1355
  • [7] CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
    Kim, Dong-Wan
    Kim, Sang-We
    Camidge, D. Ross
    Shu, Catherine A.
    Marrone, Kristen A.
    Le, Xiuning
    Blakely, Collin M.
    Park, Keunchil
    Chang, Gee-Chen
    Patel, Sandip Pravin
    Kar, Gozde
    Cooper, Zachary A.
    Samadani, Ramin
    Pluta, Michael
    Kumar, Rakesh
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 650 - 656
  • [8] Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer
    Allard, Bertrand
    Turcotte, Martin
    Stagg, John
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (08) : 863 - 881
  • [9] Overcoming resistance to EGF receptor tyrosine kinase inhibitors in EGFR-mutated NSCLC
    Saad, Shumaila
    Huang, Kan
    Halmos, Balazs
    LUNG CANCER MANAGEMENT, 2014, 3 (06) : 459 - 476
  • [10] Characterisation of novel CD73 antibodies as a therapeutic method of adenosine regulation
    Gernon, Grainne
    Grooby, Suzanne
    Tonkin, Louise
    Bitterwolf, Anja-Christina
    Stewart, Lorna
    Deken, Marcel
    Shah, Pritom
    Ewings, Katherine
    Johnson, Zoe
    CANCER RESEARCH, 2020, 80 (16)
12345